ISN Journal Editorial Selections
Kidney International®
Novel Anemia Therapies in CKD: Conclusions from a KDIGO Controversies Conference
The conference, held virtually in December 2021, reviewed new evidence on diagnosing and managing anemia in chronic kidney disease (CKD). The meeting focused on a new class of agents—the hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs).
HIF-PHIs are reported to be non-inferior to conventional Erythropoiesis-Stimulating Agents in managing hemoglobin levels and reducing transfusion needs in both non-dialysis and dialysis CKD patients.
However, concerns about cardiovascular safety persist, and there is no conclusive evidence supporting a reduction in the need for iron supplementation or improved anemia correction in states of chronic inflammation with HIF-PHIs.
Kidney International Reports®
The conference, held in May 2022, tackled the challenge of dealing with symptoms in dialysis patients. They discussed ways to:
- Incorporate symptom assessment into routine care
- Ease physical symptoms
- Improve the management of psychological symptoms
- Find system-level approaches for better symptom management.
The conference outcomes show that healthcare experts in kidney health are committed to making sure symptoms are assessed and managed in a personalized way and become part of routine clinical care.
